摘要
目的探讨电化学发光免疫分析技术(ECLIA)测定血清细胞角蛋白19片段(CYFRA21-1)等肿瘤标志物及其临床应用。方法应用ECLIA法对53例肺癌患者血清CYFRA21-1、NSE、CEA含量进行测定,并与41例肺部良性疾病患者和40例正常健康对照者进行对照分析。结果肺癌患者血清CYFRA21-1、NSE、CEA水平明显高于肺部良性疾病组和正常对照组(P<0.01)。CYFRA21-1在肺鳞癌中表达水平最高,NSE肺小细胞癌中表达水平最高,CEA在肺腺癌中表达水平最高。血清CYFRA21-1+NSE+CEA联合检测肺癌的的敏感性为88.7%,特异性为85.2%,阳性预测值为92.2%,阴性预测值为92.0%,准确性为86.6%。手术根治及放/化疗有效组患者术后CYFRA21-1、NSE、CEA水平明显下降(P<0.01),而对放/化疗抵抗的患者三者水平在治疗前后变化不明显(P>0.05)。结论检测血清CYFRA21-1对肺癌诊断具有重要的临床参考价值,联合检测NSE、CEA可提高检测肺癌的敏感性和准确性,并为肺癌的病理类型评估、病情监视及疗效判断提供依据。
Objective To study the clinical value of cytokeratin 19 fragment（CYFRA21-1） and other associated tumor markers in diagnosing lung cancer. Methods Serum levels of CYFRA21-1,NSE and CEA were Investigated in 53 cases of lung cancer, 41 cases of benign lung disease and 40 cases of normal controls by electrochemiluminescence immunoassay（ECLIA）. Results The levels of CYFRA21-1,NSE and CEA in lung cancer group were significantly higher than those in group with benign lung disease and the control group （P 〈0.01）. Patients with squamous cell carcinoma of lung had highest CYFRA21-1 level, patients with small cell lung carcinoma had highest NSE level, while lung adenocarcioma patients had highest CEA level, when combining detection of the three tumor markers was used for the diagnosis of lung cancer, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 88.7%, 85.2%, 92.2%, 92.0%, and 86.6%, respectively. After operation, a marked decrease of three tumor marker levels was observed（P 〈 0.01）. No obvious difference in the levels of serum CYFRA21-1, NSE, and CEA were observed before and after treatment in the radiotherapy/chemotherapy resistance group （ P 〉 0.05）. Conclusion This results suggest that the serum CYFRA21-1 is of clinical importance for the diagnosis of lung cancer. Combination of NSE and CEA can improve the diagnostic sensitivity and accuracy, especially in providing evidence for lung cancer in predicting the pathological type, diagnosing patients＇ condition, and evaluating therapetic effect of lung cancer.
出处
《中国微循环》
北大核心
2005年第5期339-342,共4页
Journal of Chinese Microcirculation
